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IMMUNOLOGICAL MARKERS OF ANTI-TUMOR DENDRITIC CELLS 
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Aim: To investigate the quantitative and functional status of peripheral blood lymphocytes in patients with non-small cell lung 
cancer during DC-vaccine therapy and identify the most informative immunological parameters which are associated with clinical 
outcome. Materials and Methods: The study was conducted within the framework of randomized phase III clinical trial of DC-
vaccine efficacy in patients with non-small cell lung cancer. Quantitative composition of peripheral blood lymphocytes was determined 
by flow cytometry. Cytokines mRNA expression level was estimated using real-time RT-PCR. Results: In our study the most 
pronounced changes in the immune system have been defined after fourth DC-vaccine injection. Immunologic features such as re-
duction the MIP-1α mRNA expression level, increasing the RANTES mRNA expression level and NK-cells count, retention CD4/
CD8 ratio at physiological level were associated with favorable clinical outcome after DC-immunotherapy. Conclusions: Immuno-
logical markers established in our investigation can be used for estimation of DC-immunotherapy efficiency. The results of our 
research are very promising, but these data should be confirmed in further studies with a large cohort of patients.
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L�ng carcinoma is the leading ca�se of cancer 
mortality worldwide. Altho�gh �-year s�rvival rate 
has tripled from �% to ��% over the last �� years� the 
estimated n�mber of deaths still exceeds �.� million 
ann�ally. The overall �-year s�rvival of l�ng cancer 
is only ��% in E�rope and ��% in the United States 
[�]. In Ukraine l�ng cancer remains the prevalent no-
sological form of cancer with an estimated �6 4�� new 
cases and �� ��� deaths in ����. Non-small cell l�ng 
cancer �NSCLC� acco�nts 8��8�% of all l�ng cancer 
cases [�].
Patients with early-stage NSCLC have relatively 
high long-term s�rvival rates after s�rgical resection� 
b�t a s�bstantial majority of patients �~7�%� are di-
agnosed with advanced or metastatic stages �stage 
III�IV� [�]. S�ch patients are treated with a variety 
of therapies incl�ding s�rgery� radiation� and che-
motherapy. Unfort�nately� s�rvival with even stage 
III disease is dismal by any meas�re and has been 
remarkably resistant to improvement despite more 
intensive standard chemotherapy� s�rgery� and/or ra-
diation therapy. The poor prognosis in NSCLC is d�e 
to its high aggressiveness� early metastasis and high 
rec�rrence rate [4� �].
New approaches in imm�notherapy offer hope 
of prolonged s�rvival in selected patients with ad-
vanced NSCLC. The great interest in this regard is the 
�se of anti-t�mor vaccines� in partic�lar� dendritic-
cell-based a�to vaccines. Antigen presenting den-
dritic cells �DC� are �sed as powerf�l nat�ral adj�vant 
to enhance the imm�ne response to t�mor antigens. 
This method aims to activate a specific anti-t�mor im-
m�nity in order to prevent rec�rrence and metastasis 
after primary treatment of cancer [6].
The rationale behind DC-based imm�notherapy 
is that injected DC ind�ces a t�mor-specific imm�ne 
response res�lting in t�mor shrinkage/clearance. So� 
ideally we sho�ld be able to identify patients that re-
spond to therapy by analyzing the anti-t�mor imm�ne 
response generated by the DC vaccine. However� 
to date� limited st�dies have shown a correlation be-
tween imm�ne and clinical responders [7].
In contrast to chemotherape�tic agents� anti-t�mor 
vaccines and other imm�notherapies that target the 
patient’s imm�ne system need first to reprogram the 
pattern of interactions between the imm�ne system 
and the t�mor. Imm�notherapy ind�ces novel pat-
terns of the antit�mor response not capt�red by World 
Health Organization criteria or Response Eval�ation 
Criteria in Solid T�mors �RECIST� which are commonly 
�sed for chemotherapy assessment. Th�s� is a needed 
new eval�ation criteria for imm�notherapy efficiency 
assessment.
In late ���� and ���� the Society for Imm�nother-
apy of Cancer �SITC�� convened an “Imm�notherapy 
S�mmit” with representatives from imm�notherapy 
organizations of E�rope� �apan� China and North 
America to disc�ss collaborations to improve develop-
ment of cancer imm�notherapy. The SITC Taskforce 
on Imm�notherapy Biomarkers addressed the lack 
of validated biomarkers for monitoring the of imm�ne 
response development of a following therapy and iden-
tified challenges critical for the translation of cancer 
imm�notherapies. Eight of the nine challenges identi-
fied by this Taskforce were related to imm�nological 
monitoring considerations [8].
D�ring last five years several imm�ne response 
assays �ELISPOT� HLA-peptide tetramers� intracell�lar 
cytokine staining and CFSE assay� have been devel-
oped and become commonly �sed. However� res�lts 
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from T-cell imm�ne response assays are highly vari-
able and often not reprod�cible. Therefore� the investi-
gation of the cell�lar imm�ne response as a biomarker 
and testing it for clinical s�rrogacy remains relevant 
problem of imm�ne therapy in cancer. Moreover for 
estimation of imm�nological efficiency of anti-t�mor 
imm�notherapy� it is necessary to determine the 
q�antity of lymphocyte s�bpop�lation� as well as their 
f�nctions� along with the cytokine and chemokine gene 
expression profiles [�].
The aim of o�r st�dy was to investigate the q�an-
titative and f�nctional stat�s of main lymphocyte s�b-
sets in peripheral blood of NSCLC patients at co�rses 
of DC vaccine administration in order to determine the 
most informative imm�nological criteria of vaccine 
efficiency. The st�dy was cond�cted within the frame-
work of randomized phase III clinical trial of DC-vaccine 
efficacy in NSCLC patients.
MATERIALS AND METHODS
Patient characteristics and treatment scheme. 
��� patients with IIB�IIIA stage of NSCLC �median age: 
6� years� range: 4��8�; males: ��� females: �� treated 
in the Department of Thoracic Oncology� National 
Cancer Instit�te of Ukraine from ���� to ���� were 
enrolled into the st�dy. Patients were randomly divided 
into � gro�ps: � — patients received standard treat-
ment �only s�rgery�; � — s�rgery and DC-vaccine. 
The DC-vaccine treatment was given 7��4 days after 
s�rgery. DCs in amo�nt 4�6� ± ���7×��6 per injection 
were administered intraveno�sly in co�rse consisted 
of 4 injections with one-month interval. The scheme 
of DC-vaccine imm�notherapy is presented on Fig. �.
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Fig. 1. Scheme of DC-vaccine imm�notherapy
Adverse effects were eval�ated according to the 
NCI Common Toxicity Criteria. Clinical and imm�-
nological monitoring of DC-vaccine imm�notherapy 
was performed at the beginning of the treatment and 
before each vaccination. An informed consents were 
obtained from patients according to the the Ethical 
Commission req�irements of the National Cancer In-
stit�te of Ukraine. According to the clinical o�tcome� 
patients who received DC — imm�notherapy were 
divided into � gro�ps: a gro�p of patients who are alive 
witho�t rec�rrence within � years period� and patients 
who developed rec�rrence d�ring this observation 
period. Follow-�p period was 6 years.
DC –vaccine preparation. Peripheral blood 
monon�clear cells �PBMCs� were isolated from ���
��� ml of heparinized whole blood samples by Ficoll 
�ρ = ���77 g/см�� density gradient centrif�gation �“Bio-
Clot”� Germany�. A�tologo�s DCs were grown from 
PBMCs by in vitro c�ltivation in RPMI-�64� �“Sigma”� 
USA� s�pplemented with �% a�tologo�s plasma and 
cytokines GM-CSF� IL-4 and IFN-α at �7 °C in a h�-
midified �% CO� atmosphere. Mechanically activated 
microparticles of lyophilized a�tologo�s t�mor cells 
were added on the 6-th day of DCs c�ltivation. Vaccine 
criteria incl�de a negative bacterial contamination and 
a f�lly mat�re DC phenotype �CD86+� CD8�+ and HLA-
DR+� that was confirmed by flow cytometry analysis. 
A�tologo�s DCs with expression of s�rface markers 
CD86 and HLA-DR at least 7�%� CD8� — ��% were 
�sed for treatment.
IMMUNOLOGICAL MONITORING
Lymphocyte phenotype analysis by flow cy-
tometry. Peripheral veno�s blood ���� ml� was drawn 
into heparinized t�bes. The following anti-h�man 
monoclonal antibodies �mAb� were �sed for flow 
cytometry: anti-CD�-PC�� anti-CD4-FITC� anti-CD8-
PE� anti-CD�6-FITC �“Beckman Co�lter”� USA�. After 
imm�nofl�orescent staining� the cells were fixed with 
�% paraformaldehyde and then analyzed by a FAC-
SCalib�r flow cytometer �sing CellQ�est-PRO soft-
ware �“Becton Dickinson”� USA�. The acq�isition and 
analysis gates were restricted to the lymphocyte gate 
as determined by their characteristics forward �FSC� 
and side-scatter �SSC� properties. FSC and SSC were 
set in a linear scale. For analysis � × ��4 lymphocytes 
were acq�ired. Cell expressing CD markers were ac-
q�ired and analyzed in the FL� or FL� logarithmic scale 
�sing the set gates.
Gene expression analysis by quantitative real-
time RT-PCR. Freshly isolated PBMCs were washed 
three times with PBS� soaked overnight in RNAlater so-
l�tion �“Ambion”� USA� and kept frozen �ntil �se. Total 
RNA was extracted from ��6 cells �sing N�cleoSpin® 
RNA II �“Macherey Nagel”� Germany� and treated with 
DNase �“Ambion”� USA�. Concentration of p�rified 
RNA was determined by meas�ring the absorbance 
at �6� nm �sing Nanodrop ���� �“Thermo Scientific 
Inc”� USA�. cDNA was synthesized from ��� ng total 
RNA in a �� µl reaction mixt�re �sing the High-Capacity 
cDNA Reverse Transcription Kit with RNase Inhibitor 
�“Applied Biosystems”� USA�. Q�antitative Real-time 
PCR was performed in a total vol�me of �� µl con-
taining � µl of cDNA� ���� µl �X Maxima SYBR Green 
qPCR Master Mix �“Thermo Scientific Inc”� USA�� 
���� µM of each specific sense and anti-sense prim-
ers on ABI Prism 7��� Seq�ence Detection System 
�“Applied Biosystems”� USA� �sing Software Version 
�.�.�. The PCR cycling conditions incl�ded an initial 
denat�ration at �� °C �� min� and �� °C ��� min�� fol-
lowed by 4� cycles at ��°C ��� s� and 6� °C �� min�. 
Melt-c�rve analysis was performed immediately after 
the amplification protocol to determine if nonspe-
cific prod�cts were amplified. The mRNA level was 
normalized by ho�sekeeping gene glyceraldehyde 
�-phosphate dehydrogenase �GAPDH�. Primers were 
designed �sing Primer Express Software v�.� and 
synthesized by Assay-by-Design service �“Applied Bio-
systems”� USA�: IFN- γ sense primer: CCA-ACG-CAA-
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AGC-AAT-ACA-TGA� IFN-γ anti-sense primer: TTT-
TCG-CTT-CCC-TGT-TTT-AGC-T; CCL� sense primer: 
ACC-ACA-CCC-TGC-TGC-TTT-G; CCL� anti-sense 
primer: GCG-GTT-CTT-TCG-GGT-GAC-A; MIP-�α 
sense primer: CAT-CAT-TTG-CTG-CTG-ACA-CG� MIP-
�α antisense primer: TGT-GGA-ATC-TGC-CGG-GAG; 
GAPDH sense primer: TGC-ACC-ACC-AAC-TGC-TTA-
GC� GAPDH anti-sense primer: CAC-GAT-ACC-AAA-
GTT-GTC-ATG-GA. Q�antitative Real-time PCR was 
performed in triplicate and repeated in at least three 
separate experiments �sing the previo�s conditions.
Statistical analysis. Statistical analyses were 
performed by STATISTICA 6.�. To determine data 
statistical significance for normal distrib�tion we �sed 
St�dent’s t-test� the val�es p < �.�� were considered 
as significant. Mann — Whitney test was �sed for 
comparison of two independent gro�ps and Wilcoxon 
test — for comparison of two dependent gro�ps for 
nonparametric data.
RESULTS AND DISCUSSION
DC-imm�notherapy was well tolerated witho�t 
significant toxicity. Only ��% of patients demonstrated 
short time temperat�re increase �abo�t �8 °C�. It has 
been fo�nd that distant rec�rrences had occ�rred 
for ��% ���/6�� of patients received only s�rgery 
�disease-free period — �.�� ± �.�7 months� and only 
for ��% �6/6�� of patients treated with DC-vaccine 
�disease-free period — �4.�� ± �.�� months�.
In f�rther researches� patients treated with DC-
vaccine were divided into � gro�ps: non relapsed �NR� 
and relapsed �R� patients.
The analysis of q�antitative stat�s of lymphocyte 
s�bsets revealed that the total n�mber of T and B cells 
for R-gro�p didn’t differ significantly from NR-gro�p. 
Statistically significant differences between NR- and 
R-gro�ps among s�bsets of CD4+ T-lymphocytes 
and CD�6+-nat�ral killer cells �NK� were observed 
at different stage of DC-vaccine therapy. It sho�ld 
be mentioned that the differences were determined 
in the absol�te val�es of these cells b�t not in their 
percentages. The res�lts are presented on Fig. �.
Th�s� for NR-gro�p patients absol�te co�nts 
of CD4+-cells were ����6 ± ���8�×���/L before 
DC-vaccine therapy and ��.�7 ± �.���×���/L after 
IV injection of DC-vaccine� whereas for R-gro�p — 
��.6� ± �.���×���/L against ��.4� ± �.�7�×���/L� re-
spectively� p < �.��. The n�mber of CD4+-cells prior 
to imm�notherapy was significantly lower in R-gro�p 
compared to NR-gro�p patients� p < �.�� �Fig. � b�.
We have fo�nd that the n�mber of main imm�ne 
effectors of imm�ne s�rveillance� NK-cells� was 
significantly higher for R-gro�p compared to NR-
gro�p patients before the vaccine therapy. M�ltidi-
rectional changes of lymphocytes s�bsets q�antities 
d�ring the co�rses of the DC vaccine therapy were 
observed. Th�s the NR-gro�p CD8+-cells absol�te 
co�nts slightly increased d�ring the DC-vaccine 
therapy� while NK-cells increased significantly from 
��.�8 ± �.�4�x���/L to ��.6� ± �.�8�x���/L� p <�.��. 
Meanwhile� for R-gro�p patients an increase of CD8+- 
and abr�pt increase NK-cells co�nts after I injection 
of DC-vaccine was noticed and followed by a decrease 
after II injection. The amo�nt of CD8+-cells before 
vaccination was ��.�4 ± �.���x���/L against ��.6� ± 
�.���x���/L after IV injection� and the amo�nt of NK-
cells — ��.6� ± �.���x���/L against ��.�� ± �.�6�x���/L� 
respectively.
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Fig. 2. Q�antitative val�es of lymphocyte s�bsets in peripheral blood of NSCLC patients. CD�6+ �a�� CD4+ �b� CD8+ �c� absol�te cell 
co�nts and CD4+/CD8+ ratio �d� before vaccine therapy �Pre� and after DC-vaccine injections �I� II� III and IV respectively�
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Patients with disease progression �R-gro�p� d�ring 
the treatment had initially low CD4+/CD8+ ratio� which 
didn’t increase d�ring the treatment. Whereas for the 
NR-gro�p patients CD4+/CD8+ rate increased after the 
first co�rse of DC-vaccine administration.
For the anti-t�mor imm�ne response monitoring 
the analysis of lymphocyte co�nts is not s�fficient 
as it doesn’t reveal their f�nctional activity. Estimation 
of the cytokine prod�ction levels of PBMCs as a f�nc-
tional state of the cells is essential. Hence one of the 
tasks of o�r research was to examine the f�nctional stat�s 
of PBMCs for the patients d�ring DC-vaccine therapy.
It is known that IFN-γ provides a connection 
between lymphocytes and macrophages and stim�-
lates of antigen-presenting cells �APC� f�nctioning� 
increases secretion of IL-� and IL-��� adj�sts the ac-
tivity of cell�lar and h�moral links of imm�ne system� 
specifically enhances cell�lar and inhibits h�moral 
imm�ne response. In addition� IFN-γ is a key factor 
for differentiation of CD4+-lymphocytes to Th�-cells. 
According to several a�thors� the elevated ser�m 
level of IFN-γ d�ring vaccine therapy may consider 
as predictive factor for rec�rrence risk assessment 
in patients with colorectal cancer� prostate cancer.
We have observed that mRNA expression level 
of IFN-γ for R-gro�p patients was significantly higher 
at almost all vaccine therapy stages in comparison with 
NR-gro�p. The IFN-γ mRNA expression level is shown 
on Fig. � a.
Imm�ne responses against cancer rely �pon 
le�kocyte trafficking patterns that are coordinated 
by chemokines� small cytokines with selective che-
moattractant properties that coordinate tiss�e homeo-
stasis and inﬂammation. The C-C motif chemokines� 
s�ch as CCR� ligands — RANTES� MIP-�α and MIP-�β 
�CCL�� CCL� and CCL4� play a cr�cial role in chemoat-
traction and activation of imm�ne cells. CCR� and its 
ligands reg�late comm�nication between CD4+� APC 
and CD8+ cells in the draining lymph nodes� drive t�mor 
infiltration by T and NK-cells� enhance the effector 
cells activity which leads to the elimination of t�mor 
cells [��].
CCR� ligands exert major reg�latory effects 
on CD4+- and CD8+ T cell-mediated imm�nity. CCR� li-
gation boosts T-cell t�mor response by mod�lating 
helper-dependent CD8+ T-cell activation with g�iding 
these cells to prod�ctive CD4+/APC complexes [��].
Despite both RANTES and MIP-�α are potent 
proinflammatory chemokines and share common re-
ceptors� their effects on the imm�ne cells have some 
pec�liarities. RANTES is considered as a T cell-specific 
chemokine� it acts as a potent chemoattractant for 
many cell types s�ch as monocytes� NK-cells� memory 
T cells and DCs. RANTES is also known to reg�late 
T cell differentiation toward Th� s�btype and req�ired 
for normal T cell f�nctions as well as for recr�iting 
CD8+ and CD4+ T cells to inflammation sites [��� ��]. 
Altho�gh MIP-�α �as well as RANTES� is a CCR� ligand 
involved in T cell traffic� it is a potent chemoattractant 
for immat�re �b�t not mat�re� DCs and macrophages. 
Moreover� MIP-�α governs B-cells chemotaxis 
and mod�lates CD4�� CD8�� and CD86 expression 
by B���+ cells� promoting h�moral response [��� 
�4]. In this manner� it can be ass�med that preva-
lence of RANTES against MIP-�α leads to selective 
enhancement of Th-� cells� cytotoxic T lymphocytes� 
and NK-cell-mediated type � imm�nity vers�s h�moral 
type � imm�nity.
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Fig. 3. Cytokines mRNA expression in PBMCs of NSCLC patients. IFN-γ �a�� RANTES �b� MIP-�α �c� mRNA levels and RANTES/
MIP-�α ratio �d� before vaccine therapy �Pre� and after DC-vaccine injections �I� II� III and IV respectively�; a.�. — arbitrary �nits
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We have shown a statistically significant difference 
in the expression levels of RANTES and MIP-�α for 
both st�died gro�ps prior to the imm�notherapy. Th�s� 
RANTES mRNA expression level for NR-gro�p pa-
tients was �6-fold higher than for R-gro�p �p < �.���� 
whereas MIP-�α mRNA expression level was � times 
lower� respectively �p < �.���. It sho�ld be mentioned 
an �nidirectional change of chemokine levels for both 
gro�ps after DC-vaccine administration. For NR-gro�p 
of patients a highest RANTES expression was ob-
served after III injection of DC-vaccine administration� 
comparable dynamics were fo�nd for R-gro�p.
The level of MIP-�α expression for NR-gro�p re-
mained at physiological val�es� whereas for R-gro�p 
patients it increased after each s�bseq�ent adminis-
tration of DC-vaccine� and reached maxim�m val�es 
after III injection of DC� p < �.��. The analysis res�lts 
of chemokines RANTES and MIP-�α mRNA expression 
levels are shown on Fig. � b, c.
Analyzing RANTES and MIP-�α mRNA expression 
levels we have fo�nd that RANTES/MIP-�α ratio was 
�4��� times higher for NR-gro�p patients compared 
to R-gro�p after I-III DC vaccine administrations� 
p < �.�� �Fig. � d�.
Th�s� changes in the imm�ne system ind�ced 
by the DC-vaccine which are associated with favor-
able clinical o�tcome consist in red�ction the MIP-�α 
mRNA expression level� increasing the RANTES mRNA 
expression level and NK-cells co�nt� retention CD4/
CD8 ratio at physiological level d�ring DC-vaccine 
imm�notherapy. Imm�nological markers established 
in o�r investigation can be �sed for estimation of DC-
imm�notherapy efficiency. The res�lts of o�r research 
are very promising� b�t these data sho�ld be confirmed 
in f�rther st�dies with a large cohort of patients.
In concl�sion� the most prono�nced changes in the 
imm�ne system have been defined after fo�rth DC-
vaccine injection. In o�r st�dy no association between 
IFN-γ mRNA expression level and clinical o�tcome for 
NSCLC patients who received DC-vaccine have been 
fo�nd. The n�mber of NK-cells� CD4/CD8 ratio� MIP-
�α and RANTES mRNA expression levels are the most 
important imm�nological markers which are associ-
ated with favorable clinical o�tcome after DC-vaccine 
therapy for NSCLC patients. RANTES/ MIP-�α mRNA 
expression level ratio at initial stage of DC-vaccine 
therapy co�ld be considered as the most s�bstantial 
marker for prognosis of its effectiveness for NSCLC 
patients.
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